333 related articles for article (PubMed ID: 32767330)
21. MicroRNA-142-3P suppresses the progression of papillary thyroid carcinoma by targeting FN1 and inactivating FAK/ERK/PI3K signaling.
Jiang Y; Liu Y; Zhang Y; Ouyang J; Feng Y; Li S; Wang J; Zhang C; Tan L; Zhong J; Zou L
Cell Signal; 2023 Sep; 109():110792. PubMed ID: 37406787
[TBL] [Abstract][Full Text] [Related]
22. STAT1-induced upregulation of lncRNA LINP1 promotes cell proliferation and inhibits apoptosis via AMPK signaling pathway in papillary thyroid cancer.
Li HP; Yang TZ; Wei L; Ge YF; Meng QS
Eur Rev Med Pharmacol Sci; 2020 Sep; 24(17):8911-8917. PubMed ID: 32964981
[TBL] [Abstract][Full Text] [Related]
23.
Wen J; Lin B; Lin L; Chen Y; Wang O
Aging (Albany NY); 2020 Aug; 12(16):16437-16456. PubMed ID: 32857728
[TBL] [Abstract][Full Text] [Related]
24. High expression of LINC0163 promotes progression of papillary thyroid cancer by regulating epithelial-mesenchymal transition MITF.
Gao P; Jiao H; Zhe L; Cui J
Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5504-5511. PubMed ID: 32495885
[TBL] [Abstract][Full Text] [Related]
25. ALDH5A1 acts as a tumour promoter and has a prognostic impact in papillary thyroid carcinoma.
Deng XY; Gan XX; Feng JH; Cai WS; Wang XQ; Shen L; Luo HT; Chen Z; Guo M; Cao J; Shen F; Xu B
Cell Biochem Funct; 2021 Mar; 39(2):317-325. PubMed ID: 32881051
[TBL] [Abstract][Full Text] [Related]
26. Eva-1 homolog A promotes papillary thyroid cancer progression and epithelial-mesenchymal transition via the Hippo signalling pathway.
Lin BY; Wen JL; Zheng C; Lin LZ; Chen CZ; Qu JM
J Cell Mol Med; 2020 Nov; 24(22):13070-13080. PubMed ID: 32969138
[TBL] [Abstract][Full Text] [Related]
27. Growth-associated protein 43 promotes thyroid cancer cell lines progression via epithelial-mesenchymal transition.
Zheng C; Quan RD; Wu CY; Hu J; Lin BY; Dong XB; Xia EJ; Bhandari A; Zhang XH; Wang OC
J Cell Mol Med; 2019 Dec; 23(12):7974-7984. PubMed ID: 31568662
[TBL] [Abstract][Full Text] [Related]
28. Propofol suppresses migration, invasion, and epithelial-mesenchymal transition in papillary thyroid carcinoma cells by regulating miR-122 expression.
Li Y; Zeng QG; Qiu JL; Pang T; Wang H; Zhang XX
Eur Rev Med Pharmacol Sci; 2020 May; 24(9):5101-5110. PubMed ID: 32432774
[TBL] [Abstract][Full Text] [Related]
29. Testosterone promotes the migration, invasion and EMT process of papillary thyroid carcinoma by up-regulating Tnnt1.
Jiang C; Xu F; Yi D; Jiang B; Wang R; Wu L; Ding H; Qin J; Lee Y; Sang J; Shi X; Su L
J Endocrinol Invest; 2024 Jan; 47(1):149-166. PubMed ID: 37477865
[TBL] [Abstract][Full Text] [Related]
30. MiR-630 inhibits papillary thyroid carcinoma cell growth, metastasis, and epithelial-mesenchymal transition by suppressing JAK2/STAT3 signaling pathway.
Pan XM; He XY; Yang YL; Jia WJ; Yang ZQ; Yan D; Ma JX
Eur Rev Med Pharmacol Sci; 2019 Mar; 23(6):2453-2460. PubMed ID: 30964171
[TBL] [Abstract][Full Text] [Related]
31. MicroRNA-26a suppresses the malignant biological behaviors of papillary thyroid carcinoma by targeting ROCK1 and regulating PI3K/AKT signaling pathway.
Wu YC; Li SY; Jia YF
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(20):8940-8949. PubMed ID: 31696481
[TBL] [Abstract][Full Text] [Related]
32. Src inhibitors in suppression of papillary thyroid carcinoma growth.
Henderson YC; Toro-Serra R; Chen Y; Ryu J; Frederick MJ; Zhou G; Gallick GE; Lai SY; Clayman GL
Head Neck; 2014 Mar; 36(3):375-84. PubMed ID: 23729178
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of long noncoding RNA SLC26A4-AS1 inhibits the epithelial-mesenchymal transition via the MAPK pathway in papillary thyroid carcinoma.
Wang DP; Tang XZ; Liang QK; Zeng XJ; Yang JB; Xu J
J Cell Physiol; 2020 Mar; 235(3):2403-2413. PubMed ID: 31556116
[TBL] [Abstract][Full Text] [Related]
34. Combretastatin A4 Regulates Proliferation, Migration, Invasion, and Apoptosis of Thyroid Cancer Cells via PI3K/Akt Signaling Pathway.
Liang W; Lai Y; Zhu M; Huang S; Feng W; Gu X
Med Sci Monit; 2016 Dec; 22():4911-4917. PubMed ID: 27966519
[TBL] [Abstract][Full Text] [Related]
35. microRNA-124-3p inhibits tumourigenesis by targeting mitogen-activated protein kinase 4 in papillary thyroid carcinoma.
Sun Y; Zhang L; Zhang S
Cell Biochem Funct; 2020 Dec; 38(8):1017-1024. PubMed ID: 32495394
[TBL] [Abstract][Full Text] [Related]
36. IL-34 is a potential biomarker for the treatment of papillary thyroid cancer.
Zhang P; Zhang H; Dong W; Wang Z; Qin Y; Wu C; Dong Q
J Clin Lab Anal; 2020 Aug; 34(8):e23335. PubMed ID: 32573824
[TBL] [Abstract][Full Text] [Related]
37. LncRNA SNHG12 promotes the proliferation and metastasis of papillary thyroid carcinoma cells through regulating wnt/β-catenin signaling pathway.
Ding S; Qu W; Jiao Y; Zhang J; Zhang C; Dang S
Cancer Biomark; 2018; 22(2):217-226. PubMed ID: 29630517
[TBL] [Abstract][Full Text] [Related]
38. LncRNA RGMB-AS1 is activated by E2F1 and promotes cell proliferation and invasion in papillary thyroid carcinoma.
Zhang Z; Li SY; Zhang LB
Eur Rev Med Pharmacol Sci; 2018 Apr; 22(7):1979-1986. PubMed ID: 29687852
[TBL] [Abstract][Full Text] [Related]
39. LDOC1 inhibits proliferation and promotes apoptosis by repressing NF-κB activation in papillary thyroid carcinoma.
Zhao S; Wang Q; Li Z; Ma X; Wu L; Ji H; Qin G
J Exp Clin Cancer Res; 2015 Dec; 34():146. PubMed ID: 26637328
[TBL] [Abstract][Full Text] [Related]
40. miRNA-21 promotes cell proliferation and invasion via VHL/PI3K/AKT in papillary thyroid carcinoma.
Zang C; Sun J; Liu W; Chu C; Jiang L; Ge R
Hum Cell; 2019 Oct; 32(4):428-436. PubMed ID: 31161410
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
